Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space
Abstract Despite the proven success of hormonal therapy for prostate cancer using chemical or surgical castration, most patients eventually will progress to a phase of the disease that is metastatic and shows resistance to further hormonal manipulation.This has been termed metastatic castrate-resistant prostate cancer (mCRPC).Despite this designati